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Summary 
The strong reaction of T cells against foreign major histocompatibility complex (MHC) antigens, 
commonly termed "alloreactivity",  is not only a nuisance for clinical organ transplantation;  it 
also remains a puzzling question for immunologists. By making use of recent technical developments, 
alloreactive T cells nominally directed against a mutation in a single MHC class I molecule were 
found to fall into several major categories. One is recognizing peptides whose occurrence is dependent 
on one particular MHC allele, another is recognizing peptides supported by several MHC alleles, 
and a third is recognizing peptides occurring independently of MHC alleles. In a fourth category, 
the binding to MHC of any of a broad range of peptides appears sufficient. In addition, there 
are T cells for which no peptide involvement could be detected at all. Even within these categories, 
the heterogeneity of T cells is considerable: among 16 Kb-reactive T cells analyzed, 15 different 
modes of reactions were found. 
T 
he trait leading to the discovery of MHC  genes 54 yr 
ago was the exquisite strength of graft rejection between 
members of a species expressing different MHC  alleles  (1, 
2). This strong in vivo reaction, which contributed the affix 
"major"  to MHC,  found its in vitro correlate later in the 
strong activation of T cells confronted by foreign MHC an- 
tigen.  The  phenomenon,  termed T  cell  alloreactivity,  is 
manifested in high frequencies of precursors specific for a given 
foreign MHC,  and in the property of unprimed T  cells to 
become activated in vitro (2-4). Both characteristics contrast 
to "normal" T  cell responses against foreign antigens, for 
example, of viral origin. In these instances, the frequency of 
antigen-specific precursors in unprimed T  cells is very low 
or undetectable, and activation of unprimed T  cells specific 
for physiologically presented foreign antigen is usually not 
observed. For physiological immune responses, it is now well 
established that T cells recognize foreign antigen as peptides 
processed by APC and presented by self MHC  molecules 
(5-12). The peptide binding site of MHC class I molecules 
has been revealed by crystallography to be a cleft built up 
by heavy chain cd and or2 domains (13,  14).  In contrast to 
these relatively well-understood topics, the phenomenon of 
T cell alloreactivity is still a puzzling question for immunol- 
ogists. 
One paper with foresight (15) suggested that alloreactive 
T cells may recognize foreign MHC plus unknown cellular 
antigens, or peptides, as we would call it now. More recent 
reports indeed indicated, by indirect means, involvement of 
non-MHC antigens (16-18). Alloreactive T cells were shown 
to recognize synthetic peptides derived from MHC sequences 
(19-21).  Another report indicated involvement of a non-MHC 
peptide in allorecognition in one case;  the peptide in ques- 
tion, however, had also to be produced artificially (22). A1- 
loreactivity has also been suggested to involve low affinity 
recognition of high-density alloantigens (23). It can be en- 
visaged, for example, that T cells recognizing foreign MHC 
molecules independent of any peptide meet some 105 ligands 
per cell, whereas peptide-specific T cells meet a few only (24). 
Thus, for those not recognizing peptide, a much lower affinity 
will suffice for activation. Indeed, a recent report suggested 
that peptides need not be involved in alloreactivity (25). 
We addressed the problem by taking advantage of two novel 
developments. One is the technique of extracting naturally 
processed peptides involved in the MHC  class  I-restricted 
antigen presentation pathway, as has been developed for minor 
histocompatibility and viral peptides (9-11). The other is the 
introduction of the mutant cell line, R/VIA-S, which appears 
to have a defect in peptide presentation; it can thus serve as 
a readout target for peptides that are otherwise intrinsically 
presented by all cells (26-30). Of the many possible MHC-in- 
compatible mouse strain combinations that could be used to 
raise alloreactive CTL, we used B6.C-H-2 bin1 anti-C57BL/6 
(abbreviated, bml anti-B6) in most experiments. Both strains 
differ at a mutation in the H-2K gene; the K b molecule ex- 
pressed by C57BL/6 and the K bin1 molecule differ at three 
amino acid residues located in the peptide binding cleft (31). 
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minimal  differences in the MHC  molecules of T  cells and 
target cells but still features all classic aspects of alloreactivity 
(2-4, 31). One should keep in mind, however, that unrelated 
MHC  molecules differ in many more amino  acid residues, 
including those outside the peptide binding region.  Thus, 
T cells raised against unrelated foreign MHC molecules might 
be more heterogeneous than those against an MHC mutation. 
Our results indicate that even the antigens recognized by 
mutant-specific alloreactive T cells are of considerable heter- 
ogeneity. They can be classified into several distinct catego- 
ries.  To simplify discussions  concerning this complex sub- 
ject, we propose a systematic nomenclature for the categories 
of alloreactive T  cells and  the antigens  they recognize. 
Materials  and Methods 
Animals.  C57BL/6 (abbreviated  B6; H-2KbD~), B6.C-H-2  bin1 
(bin1; KbmlDb), B6.C-H-2  b~~ (bin3;  Kbm~Db),  BALB/c (KaDd), 
BALB.B (KhDb), BALB.SR (KbDd), BALB.HTG (KaDb), B10.BR 
(KkD~), B10.D2 (KdDd), and B10.S (K'D') were bred and main- 
tained at the animal facility of Max-Planck-Institut flir Biologie. 
A 4.2-g specimen of Lumbricus terrestris was collected next to the 
parking lot of the institute. 
Cell Lines.  EL4, RMA,  RMA-S (26) (all H-2b), Jurkat,  and 
Jurkat-K  b (22) cells were maintained in RPMI 1640 supplemented 
with 5% FCS at 37~  in a 5% CO2 atmosphere. For mass cub 
tures, cells were expanded in 1 liter of DMEM (Gihco Laborato- 
ties, Grand Island, NY) supplemented with 5% FCS in 2-liter roller 
bottles (Duran; Schott Mainz, FRG) at 37~  "RMA-S(26~  '' 
or "cold RMA-S cells" indicates RMA-S cells precultured at 26~ 
for 24-48 h. 
Acid Extraction of  Peplides  frora Whole Cells.  Two to four spleens 
of the mouse strains indicated,  or 109 tumor cells suspended in 15 
ml of 0.1%  (vol/vol) TFA were homogenized by douncing (10 
strokes) using a borosilicate glass  dounce-homogenizer (15 ml; 
Braun, Melsungen, FRG). The suspension was further homogenized 
by ultrasonication (20 pulses of 1 s; sonifier model B15; Branson, 
Danbury, CT). The homogenate was stirred for 30 min at 4~  pH 
was kept at 2.0 throughout this procedure by adding 1% TFA. 
Supernatant was collected after centrifugation (150,000 g  for 30 
rain at 4~  The remaining pellet was extracted again using 7 
ml of 0.1% TFA. Combined supernatants of the first and second 
extraction were lyophilized overnight (model Gamma 1A; Christ, 
Osterode, FRG), resuspended in 2.5 ml of 0.1% TFA, and sub- 
jected to a Sephadex G25 coarse gel filtration column (Pharmacia 
Fine Chemicals, Piscataway, NJ) (bed volume, 75 ml). Material of 
Mr <5,000 was collected, lyophilized, and stored at  -70~  if not 
immediately used for HPLC separation. 
Acid Extraction of Pepa'des from  Purified MHC  Class I  Mole- 
cules.  Two slightly different methods were used.  For the first 
method, five BALB.B spleens were lysed in 20 ml of 1% NP-40 
detergent in PBS containing 0.1 mM PMSF using the douncing 
procedure as described above. The resulting suspension was stirred 
for 30 rain at 4~  and centrifuged (5 min,  250 g,  4~  The 
resulting supernatant was centrifuged again (30 rain, 150,000 g, 
4~  Supernatant from this step was incubated (under gende agi- 
tation; 5-6 h at 4~  with CNBr-activated Sepliarose CL4B beads 
(Pharmacia Fine Chemicals), to which Kb-specific K9-178 (32) or 
Db-spedfic  B22-249 (33) antibodies had been covalently coupled 
according to manufacturer's protocol (0.5 ml of beads were coated 
using 0.5 to 1 mg/ml of antibody). Beads were washed twice in 
PBS/0.5% NP-40, once again in PBS, and were subjected  to acid 
elution by vortexing in 3 ml of 0.1% TFA for 15 rain at 4~  For 
the second method, 6-8  x  109 RMA-S cells kept for 24 h at 26~ 
were detergent lysed (100 ml of PBS/1% NP-40) and treated as 
for the first method. The supernatant from the last ultracentrifu- 
gation step (100 ml) was first passed over a chromatography column 
filled with anti-K  b beads, then over a column with anti-D  b beads 
(bed volumes, 0.5 ml; flow rate, 0.25 ml/min; 4~  Loaded beads 
were removed from the columns, washed as above, and subjected 
to acid extraction as above. Supematant of  both BALt~B- and RMA- 
S-derived material was lyophilized, resuspended in 1 ml of 0.1% 
TFA, and subjected to HPLC separation. 
HPI.C Separation of  Acid Extracted Peptides.  Extracts were solu- 
bilized in 1 ml of 0.1% TFA, subjected to a reverse-phase HPLC 
column (SuperPac PepS; Pharmacia LKB) (4.0  x  250 mm, 5-/~m 
particles C2/C18), and were eluted using the following Pharmacia 
LKB equipment: HPLC-pump model 2248;  low pressure  mixer 
model 2248; variable wavelength monitor model 2141; fraction col- 
lector model Frac 100; HPLC Manager software for controlling 
elutions and for evaluating data. Elution gradient was as follows. 
Solution A, 0.1% TFA; solution B, acetonitrile containing 0.1% 
TFA. 0-5 min, 0% B; 5-40 min, linear increase to 60% B; 40-45 
min, 60% B; 45-50 min, decrease to 0% B. Flow rate, i ml/min; 
fraction size, 1 ml, HPLC separations were done at room tempera- 
ture. Individual fractions were collected into 1-ml Eppendorf tubes, 
dried by vacuum centrifugation (Speedvac; Savant, Farmingdale, 
NY), and stored at  -70~ 
Cytotoxic T  Lymphocytes.  For  generation  of the  CTL  line 
13V0-5,  spleen cells from a bml mouse (preimmunized with 107 
irradiated EL4 cells intravenously) were stimulated in vitro with 
irradiated (33 Gy from a 137Cs source) B6 spleen cells in cr-MEM 
medium supplemented with  10%  FCS for 7 d.  Thereafter, sur- 
viving cells were restimulated weekly using medium supplemented 
with Con A-induced rat spleen cell supematant as a source oflb2. 
Clones (designated 13V0-5-27.2 and so on) were derived from this 
line by limiting dilution at a seeding density of 27 or 9 cells per 
well, respectively, 10 d after the line's initiation. Growing cells were 
found in <37% of the cultures. Subclones derived from 27.B2 and 
27.7 seeded at 0.5 or 1 cell per well showed the same reactivity 
pattern (as tested with extracted peptides, see Table 2) as their pa- 
rental clones (not shown). The line 13V0-4 and its subline  81.13 
was derived from a bml mouse preimmunized with 107 B6 cells. 
The 26T0  series  are CTL lines derived from primary in vitro 
cultures.  26T0-1  is bin1  anti-B6,  26T0-3  is bm3  anti-B6,  and 
26T0-5  is  B10.HTG  anti-B6.  For  the  minor  H-specific  17S0 
series, BALB.B mice were immunized intraperitoneally with 107 
RMA cells (17S0-1) or RMA-S ceils (17S0-3). Responder spleen 
cells were stimulated in vitro with RMA or RMA-S cells, respec- 
tively, in cultures supplemented with Ib2 after day 7. Both lines 
do not kill BALB.B targets, indicating that they are specific for 
B6 minor H antigens. Both lines do not lyse the natural killer cell 
targets K562. The H-4b-specific line B21W9 and the H-Y-specific 
line 11P9 have been described (9, 34). 
CTL Assays.  Lysis of either tumor target cells or Con A-in- 
duced splenic blast calls in the absence of added Peptide (applies 
only to Table 1) was tested in a standard SlCr release assay as de- 
scribed (35),  using 4-h incubation of CTL and target cells. For 
the detection of CTL-recognized Peptides,  dried HPLC fractions 
were dissolved  in 300-650 #1 of PBS. 30-50/~1 of this solution 
was  used  to  incubate  104 51Cr-labeled RMA-S  cells  (grown  at 
normal conditions; i.e., at 37~  or EL4 cells (in Fig. 3 only) for 
90 min in a total volume of 150 #1 medium in round-bottomed 
wells of 96-well microtiter plates. CTL were added to give a total 
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followed by harvesting of supematant and determination of released 
radioactivity. Percent specific release was determined according to 
standard methods (35). 
A  Consideration on  the  Yield of Extracted Peptides.  Typically, 
'~10% of an HPLC fraction (e.g., a fraction was dissolved in 300 
/zl of PBS, and 30/~1 of this was used) was used for CTL assays. 
As can be seen from Fig.  1, b, d, f, and h, or from Fig. 4, a-e, 
this material could be further diluted by a factor of 10 for many 
of the fractions. Thus, 1/100 or less of the material extracted from 
two to four spleens is still enough to sensitize 10,000  target cells, 
at least for some of the peptides, as seen by 9.6, 27.B2, 26T0-3, 
and 27.5 CTL. On the other hand,  other peptides occur hardly 
over detection limit, e.g., fraction 24 of bm3 cells, as recognized 
by 26T0-3 CTL (Fig.  4 b). An absolute calculation on the yield 
of extracted peptides is not possible in the present cases, since their 
sequence is not known. Using the same extraction procedures, we 
have calculated  the copy number of K a- or Db-restricted viral pep- 
tides occurring in influenza-infected cells to be between 200 and 
500. Synthetic peptides admixed to noninfected cells followed by 
mock-extraction were recovered with a yield of 25-100%  (36). 
cule K s and all recognizing the Kb-expressing cell lines EL4 
and RMA, were tested on mutant RMA-S targets. The latter 
cells have been reported to express only few functional class 
I molecules if cultured at 37~  Upon culture at 26~  the 
cells express what has been called "empty" MHC class I mol- 
ecules (29).  Some of the CTL lines recognized "warm" as 
well as "cold" RMA-S cells, confirming earlier  data (30), 
whereas the remaining lines did not eflidently recognize warm 
RMA-S cells (Table 1). Since peptide-incubated  warm RMA-S 
cells can be recognized by peptide-specific CTL (27, 29), most 
of the above CTL lines were suitable for analyzing peptide 
involvement in alloreactivity.  The 13V0 series and 26T0-1 
were produced in the mouse strain combination B6.C-H- 
2  bin1 (bml;  H-2  bin1) anti-C57BL/6  (B6,  H-2b).  26T0-3  is 
bin3 anti-B6, and 26T0-5 is Bt0.HTG (KaD  b) anti-B6. Table 
1 shows the reactivity pattern of these CTL on several target 
cells. 
Isolation of Naturally  Processed "~llopeptides'~  We have re- 
cently described  an acid extraction  method  allowing isola- 
tion and analysis of naturally processed minor histocompati- 
bility  and  viral  peptides,  as  recognized  by  MHC  class 
I-restricted CTL (9, 11). This method was applied to extract 
naturally  occurring  peptides  from  Kb-expressing  B6  and 
from Kb-negative BALB/c (H-2  d) spleen cells. The extracted 
Results 
CTL Lines.  A  set of 16 different mouse CTL lines and 
clones, all nominally directed against the MHC class I mole- 
Table  1.  Recognition of Selected Target Cells by a Series of KS-reactive and Minor H-specific CTL 
Target cells* 
RMA-S 
CTL  B6  bin1  bin3  B10.HTG  BALB/c  Jurkat  Jurkat-K  b  RMA  RMA-S  (26~ 
Anti-K  b 
13V0-5  71/39/40  0/0/0  81/62/64  0/1/0  0/0/0  14/8/3  72/61/53 84/88/88  40/20/9  81/53/42 
13V0-5-27.2  18/24/41  1/3/0  27/31/28  0/0/0  0/0/0  19/11/6  51/43/52  85/98/92  35/35/30  72/73/69 
27.5#  46/35/29  0/0/0  33/46/38  0/0/0  0/0/0  21/13/6  50/51/53  79/97/90  0/1/0  11/10/4 
27.7  59/71/70  0/0/0  0/0/0  0/0/0  0/0/0  9/8/2  46/48/40  82/81/79  1/5/4  21/24/25 
27.B1  65/59/43  0/0/2  0/0/0  0/0/0  0/0/0  24/8/3  92/83/66  86/75/64  1/1/0  11/9/3 
27.B2~  59/50/60  0/1/0  0/0/5  0/0/0  0/0/0  25/12/5  95/89/86  89/75/75  33/24/12  32/23/13 
27J  93/27/6  0/0/0  0/0/0  0/0/0  1/0/0  19/10/6  37/29/21 68/57/45  0/1/1  1/0/0 
9.1  12/0/5  0/0/0  19/29/28  0/0/0  0/0/0  10/6/6  29/26/19  80/81/84  14/12/8  53/45/30 
9.5  74/64/56  1/0/0  0/0/0  0/1/0  0/0/0  18/10/2  39/38/24  81/93/85  9/11/8  99/86/72 
9.6  57/51/42  2/0/1  0/0/0  0/0/0  0/0/0  27/18/7  65/65/74  87/87/87  0/1/0  16/14/15 
9.11  14/11/9  0/0/0  5/0/0  0/0/0  0/0/0  13/8/2  54/55/46  51/45/22  1/1/1  1/0/0 
13V0-4  23/24/30  0/0/0  0/0/0  0/0/0  0/0/0  27/12/8  35/25/15  19/11/6  0/0/0  2/1/0 
13V0-4-81.13  35/13/22  0/2/5  25/21/25  0/0/0  0/0/2  19/13/7  29/18/13  77/89/78  3/1/2  11/15/14 
26T0-1  31/35/41  0/4/0  0/0/6  0/0/0  0/0/0  20/11/2  71/62/47  80/82/81  9/8/6  55/42/28 
26T0-3  46/46/31  0/0/0  0/0/0  0/0/0  0/0/0  11/10/3  41/45/42  78/79/80  14/10/7  50/43/26 
26T0-5  31/28/16  1/0/0  27/0/3  2/1/0  0/0/0  13/11/1  45/32/21  75/82/63  4/4/2  35/24/7 
Minor H-specific 
CTL 
17S0-1  45/44/42  61/22/38  54/23/31  60/30/28  2/0/0  7/6/1  12/11/5  71/92/80  14/26/20  89/84/56 
17S0-3  72/60/56  56/57/46  49/43/64  69/56/65  0/0/0  19/16/10  23/20/10  76/75/88  61/68/59  86/79/67 
* Target ceils were Con A-induced blasts from spleen cells of the strains indicated, or tumor cells. The numbers indicate specific lysis of target 
cells at relative E/T ratios of 1:1/1:3/1:9.  Starting E/T ratios ranged between 3:1 and 12:1. 
t The clones 27.5 and 27.B2 were also tested on B10.D2 and B10.S target  cells, which were not killed. 
1061  R&zschke et al. peptides were separated by reverse-phase HPLC. Warm RMA-S 
cells  were incubated  with  individual  peptide  fractions  and 
tested for recognition by alloreactive CTL.  The detailed rec- 
ognition patterns of B6 and BALB/c extracts by some selected 
CTL lines are shown in Fig.  1; a summary of the behavior 
of all CTL  lines tested  appears in Tables 2  and 3.  The data 
indicate  that  almost  every one of the  16  CTL  lines  shows 
a unique  antigen  specificity,  the majority with  peptide  in- 
volvement. 
P-el)tides  Dependent on Specific MHC AIIeles.  The done 27.7 
recognizes  a peptide eluting at fraction 26 of B6,  but not 
BALB/c extracts (Table 2, line 3). The occurrence of this pep- 
tide is MHC class I dependent (10), as indicated by its pres- 
ence  in  BALB.B  (H-2 b)  and  BALB.SR  (KbDd),  but  not 
BALB.HTG  (KaD b) extracts  (Fig.  2, a-c).  This is formally 
demonstrated by the presence of this peptide  (fraction 26) 
in Jurkat-K b, but not Jurkat cells (Fig. 2 d). The latter are 
human  tumor  ceils  with  or  without  transfected  K b (22). 
The  peptide  is  also  detected  in B10.129-H-4 b (H-2 b)  and 
129/Sv (H-2b), but not in B10.BK  (H-2k), B10.D2  (H-2d), 
or B10.S (H-2') extracts (Fig. 2 g; Table 2). Thus, the pep- 
tide is strictly dependent on expression of K b molecules but 
appears independent of non-MHC background genes.  The 
clone 9.6 is very similar in its reactivity pattern (Fig.  1 a; 
Table 2, line 9; Fig. 2, e and h); 9.6 and 27.7 actually repre- 
sent the only recurrent specificities  among the 16 CTL tested. 
The behavior of the two clones is reminiscent of that of minor 
H- or virus-specific CTL, which also recognize peptides ab- 
solutely dependent on specific MHC alleles (10, 11). Indeed, 
the peptide recognized  by 9.6  as well as the Kb-restricted 
minor  H  peptide  H-4 b could  be  eluted  from  purified  K b 
molecules (Fig. 3 a). By contrast, 9.6 did not recognize any 
peptide eluted from purified D b molecules, although the D b- 
restricted H-Y peptide could be detected (Fig. 3 b). The rda- 
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Figure  1.  Screening  of Kb-directed, alloreactive CTL on B6 and BALB/c peptide extracts. 9.6 (a and b), 27.B2 (c and d), 26T0-3  (e and J),  27.5 
(g and h), 9.1 (i), 27.B1 (/'), and 13V0-4 (k) CTL were tested for recognition of individual HPLC fractions of peptide extracts prepared from B6 (Q) 
or BALB/c (O) spleen cells, b, d, f, and h show recognition of individual HPLC fractions in titrated concentrations. OD profiles of the separated 
material are not shown in this paper, since they look essentially identical to those published in references 9 and 10. We never found any correlation 
between any particular  OD peak and an activity peak. E/T ratio was between 1:1 and 5:1, spontaneous  release  of target ceils ranged between 17.9% and 30.7%. 
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 Table  3.  CTL  Recognition of Peptide Extracts from RMA-S  Cells 
Extracts  from: 
CTL  RMA  RMA-S  RMA-S  (26~ 
13V0-5-27.5  30/31( +  + )  30/31( +  + )  24( + /  -  ),30/31( +  + ) 
27.7  26/27( +  + )  ( -  )  26( + ),31(+ ) 
27.B1  32(+  + )  ND  ND 
27.B2  24-26( +  + ),30( + )  ( -  )  ( -  ) 
13V0-4-81.13  29( + /  -  )  ND  ND 
26T0-3  24-26( +  + )  ( -  )  ( -  )* 
Peptides extracted from RMA or RMA-S cells cultured at 37~  or from RMA-S cells cultured at 26~  were tested for recognition by the CTL 
indicated. Presentation of the data is as in Table 2. 
* See Fig. 3 e. 
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Figure 2.  MHC dependency of aUopeptides.  Acid extracts from BALB.B (KbD  b) (a), BALB.5R (KbD  d) (b), BALB.HTG (KdD b) (c), B10.BR (H-2  k) 
(O), B10.D2 (H-2  a) (A), or B10.S (H-2') (.)  (g-i), or bml (/and k), or bm3 (O) and bml (O) (/) male spleens,  or Jurkat (O) and Jurkat-K  b (O) 
cells (d-J) were HPI.C separated and tested for recognition by 27.B2 (O) and 27.7 (A) CTL (a-c, k), or 27.7 (d and g),  9.6 (e, h,  and j), or 27.5 
Or, i, and I) CTL as in Fig.  1.  E/T ratio was between 5:1 and 21:1; spontaneous release ranged from 15.9%  to 28.7%. 
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Figure  3.  Extraction  of  peptides from 
purified MHC class I molecules. K  b (a) or D  b 
(b) molecules were immunoprecipitated from 
BALB.B male spleens. Peptides eluted from 
these preparations were HPLC separated and 
tested as  in  Fig.  1 for recognition by K  b- 
directed, alloreactive  CTL 9.6 (A) on KMA-S 
target cells, or by Kb-restricted, H-4b-specific 
CTL B21W9 (O), or by Db-restricted, H-Y- 
specific CTL 11P9 (~7) on EL4 target cells 
(a-d). Fractions 29 (e) and 30 (A) of a were 
assayed in titrated concentrations  with B21W9 
CTL (c), and fraction 27 of a was tested with 
9.6 CTL (d). (e) K  b or D b molecules immu- 
noprecipitated  from cold RMA-S cells  were  sub- 
jected to acid extraction. HPLC-separated  frac- 
tions of Kb-eluted peptides (0) or Db-eluted 
peptides (O) were incubated with SlCr-labeled 
RMA-S cells and assayed for recognition by 
26T0-3 CTL. E/T between 2:1 and 12:1, spon- 
taneous release between 17.3% and 30.7%. 
tive quantities of the H-4  b minor H  peptide and the allopep- 
tide recognized by 9.6 do not differ, as indicated by the titra- 
tion experiment in Fig.  3,  c and d). 
Peptides Supported by Several MHC Alleles.  The clone 27.B2 
finds its main peptide around fraction 25 of Kb-expressing 
B6 and RMA cells, as well as in bin1 and bin3 cells (Tables 
2  and 3; Fig.  2  k). To a smaller extent, this applies also to 
B10.S (see the titration experiment in Fig. 4 a), but is not 
the case with B10.BK or BALB/c cells (Fig.  1 c; Table 2). 
The peptides eluting at fraction 25 of B6, bin1, or bm3 ex- 
tracts, respectively, coelute if subjected to an HPLC gradient 
of high resolution power (not shown),  suggesting  that  all 
three are identical. The peptide can also be duted from purified 
K b, but  not from D b molecules (Table 2).  It is likely that 
this peptide is presented by K b, K bin1, K bin3, and H-2' mol- 
ecules; the clone 27.B2, however, recognizes only B6 and not 
1065  R6tzschke  et  al. 
bml, bm3, or B10.S target cells. 27.B2 recognizes, to a lesser 
extent, a peptide at fraction 29 or 30 in some cell extracts, 
for example in Fig. 1 c. This can, however, hardly be detected, 
as  seen in the titration  experiment in Fig.  I  d. 
Line 26T0-3 recognizes a peptide around fraction 24 in 
B6, Jurkat K b, and RMA cells, as well as in bm3 cells, but 
not in BALB/c, bin1, B10.BK, B10.D2, or B10.S cells (Tables 
2 and 3). The peptide is elutable from purified K b molecules 
(in addition to another peptide at 29/30,  which is not de- 
tected  in  total  cell  extracts),  but  not  from  D b molecules 
(Table 2). Thus,  26T0-3 recognizes a peptide supported by 
at least  two MHC  molecules,  K b and  K bm3. 
Exchangeable Peptides?  The line 13V0-4 recognizes pep- 
tides eluting from fractions 24 to 31 of both B6 and BALB/c 
extracts (Fig. 1 k). Since this line is undoned,  it is possible 
that this pattern reflects a multitude of peptide-spedfic clones == 
=o 
o  E 
￿9 bm3, #25 
￿9  bin1 ,~25 
￿9  B6,  #25 
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b  c 
20T0-3 y  27.   2' 
0.00~  0.~  0.001  0.1 
dilution  of  fraction 
8O  = 
g 
-~  6o 
(3. 
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N  2O 
￿9  #30,  +  proteinase  K 
￿9  #30,  no  profease 
o #30,  +  protease  (inakt.) 
d 
0.001  0.1 
e27-5 
0.001  0.1 
dilution  of fraction 
Figure 4.  Relative quantities of peptides. RMA-S cells were incubated with serially diluted fractions and tested for recognition by the CTL indicated. 
(a) fraction 25 each of bm3 (@), bml (A), B6 (V), and B10.S (I) extracts were assayed with 27.B2 CTL. (b) fraction 24 each of B6 (@) or bm3 
(A) extracts assayed with 26T0-3 CTL. (c) fraction 25 of bm3 (e) and fraction 30 each of bin3 (&) and bin1 (m) assayed with 27.5 CTL. (d and 
e) 27.5 CTL were tested for recognition of fraction 30 each of B10.D2 (d) or yeast (e) extracts. Before the assay, fractions were treated with Proteinase 
K followed by boiling (e), or by boiling alone (A), or were mixed with self-digested Proteinase K inactivated by boiling to control for competing 
peptides stemming from Proteinase K (O). Proteinase K treatment was done at 0.5 mg/ml in PBS for 2 h at 37~  followed by boiling for 3 min. 
E/T ratio, 3:1 to 6:1; spontaneous release, 15.9-28.0%. 
present in this line. However, the MHC independency of the 
peptides involved may also suggest that this line recognizes 
K b  molecules  occupied  with  any  of  a  broad  range  of 
peptides. 
Ubiquitous Peptide.  The clone 27.5  shows an intriguing 
peptide specificity. It finds a peptide at fraction 30/31 in all 
cell extracts analyzed including RMA-S cells and nontrans- 
fected human Jurkat cells (Fig.  1, g and h; Fig.  2, f, i, and 
1; Tables 2 and 3). Thus, this rather ubiquitous peptide (which 
is a genuine peptide, as shown by 99% reduction of its ac- 
tivity after proteinase K  treatment; Fig.  4 d) is completely 
MHC independent. Indeed, it cannot be eluted from purified 
K s  or D s  molecules (Table  2).  In addition,  however, the 
clone sometimes finds (to a marginal extent) a peptide at frac- 
tion 26 of B6 extracts, and 24 of cold RMA-S cells (Table 
3). The clone efficiently detects a peptide at fraction 24/25 
80 
g 
-~  60 
o 
￿9  ~  40 
N  20 
0 
o 
o 
| 
in 
CI  A  27.5  b  27.5  1 
earthworm  I 
I  c 
80  9.5 
so  yeast 
20 
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20  25  30  35 
fraction  no. 
d 
I  E.coli 
27.5 
20  25  30  35 
fraction  no. 
Figure 5.  Peptides  derived  from other 
species. The ip clone 27.5 (a, b, and d) 
and the fp-clone 9.6 (c) were tested for 
recognition of HPl.C-separated peptide 
extracts from yeast (a and c), an earth- 
worm (b), orE. coil (d). For extraction, 
2 g of Saccharorayces cerevisiae  (baker's 
yeast) was frozen and thawed five times 
and sonicated in 0.1% TFA, and fur- 
ther processed as for spleen  cells. A spec- 
imen of Lumbr/cus  terrestr/s  was chopped, 
mortared, and sonicated in 0.1% TFA. 
Half of this material was further pro- 
cessed as described  for spleen  ceils. 1.5 g 
orE. call strain C600 pellet was frozen 
and thawed  five times,  dounced  and 
sonicated in 0.1%  TFA, and further 
processed as for spleen cells. E/T ratio, 
3:1 to 6:1; spontaneous release, 15.9- 
28.0%. 
1066  Natural Peptides Recognized by Alloreactive T Cells of bm3 but not bml extracts  (Fig. 2/).  Thus, apart from 
the ubiquitous peptide, 27.5 recognizes an MHC class I-de- 
pendent peptide supported by bin3,  and probably also by 
K b. The two peptides might actually be related.  The ubiq- 
uitous one, for example, could be a precursor of the MHC- 
dependent one.  The MHC-dependent one (even if barely 
detectable,  as in context of K b) is probably the only one ac- 
tually presented by cells, and thus the one inducing the respec- 
tive alloreactive  T  cell. 
Heteroditic Peptides.  The Kb~-supported peptide recog- 
nized by 27.5 can be considered as heteroditic because it is 
apparently  more  abundant  in  bm3  cells  than  in  K b- 
expressing cells, which were used as stimulators to produce 
this clone. Another heteroclitic peptide is recognized by the 
line 81.13 (also bin1 anti B6) at fraction 28/29 of bin3, but 
is not detectable in B6 extracts  (Table 2). Both lines recog- 
nize B6 as well as bin3 target cells (Table 1), 
Peptides: Self and Nonself.  All peptides (unless eventually 
encoded by H-2K itself) recognized by the alloreactive CTL 
described in this study can be considered as self peptides from 
both the T cell's and the target cell's view, if one uses "self 
peptide" in the sense of"contained in a self protein sequence': 
The T cell compartment, however, accepts only those pep- 
tides as self that are actually processed and presented by self 
cells (37). For the sake of discussion,  we shall use the term 
"self peptide" in the latter (i.e., in the T  cell's) sense. 
The clone 27.B2  (bin1  anti-B6)  recognizes an  MHC- 
dependent peptide eluting at fraction 25 from both B6 and 
bml extracts  in similar relative quantities (Fig.  1, c and d; 
Fig.  2 k; Fig. 4 a).  Thus, 27.B2 recognizes a self peptide. 
If the very same peptide can be eluted from both purified 
K b and K bin: molecules, MHC restriction of self tolerance 
(38-40) would finally have been proven on the molecular level 
The line 26T0-3 (bin3 anti-B6) is similar to 27.B2 in this 
regard, since the MHC-dependent peptide recognized by the 
former line is produced by syngeneic bm3 cells as well. The 
relative quantity of this peptide (fr.24) is smaller in bin3 as 
compared to B6 cells (Fig.  4 b). 
The ubiquitous peptide recognized by 27.5 (bml anti-B6) 
is also produced in bml cells syngeneic to the CTL. How- 
ever, the MHC-dependent component, probably the one ac- 
tually presented by intact B6 target cells, could not be de- 
tected in bml cells. 
Peptidesfrom Mice andMen.  The clone 27.5 clearly recog- 
nizes a peptide (fr.30/31) present in the human cell line  Jurkat 
(Fig. 2j~. Since this peptide shows the same elution behavior 
on the reverse-phase HPI_C column as the one extracted from 
mouse cells (Table 2), and since it is recognized by the same 
clone, it is likely that the determinant recognized by 27.5 
in fraction 30/31  is conserved between mouse and man. 
The allopeptides extracted from Jurkat-K  b and B6 cells 
recognized by 26T0-3 CTL (Table 2) coelute on an HPLC 
gradient of high resolution (not shown). The same is found 
with Jurkat K b and B6-derived peptides recognized by 9.6 
CTL (not shown). Thus, both peptides are likely to be con- 
served between mouse and man. Alternatively, the MHC- 
dependent peptides detected by 9.6 and 26T0-3 (and also 27.7 
and 27.B2;  see Table 2) in Jurkat-K  b but not in Jurkat cells 
are derived from the transfected  K b itself. 
Peptides  from Baker's Yeast and Earthvorms.  Since 27.5 finds 
a peptide in both mouse and man, we were interested in the 
possible presence of this peptide in other taxa. The clone de- 
tects this peptide also in an annelide, Lumbricus terrestris, and 
very efficiently in SacckaromFes cerevisiae, but not in Esche- 
richia coli (Fig. 5, a, b, and d). The material extracted from 
yeast,  which is not recognized by the done 9.6 (Fig.  5 c), 
is indeed of peptidic nature, since its antigenicity is destroyed 
by proteinase K (Fig. 4 e). Thus, the peptide recognized by 
clone 27.5 appears to be conserved throughout a wide range 
of eukaryotic taxa,  but not to be present in prokaryotes. 
Can T  Cells Recognize Empty MHC Molecules?  For the 
CTL dones 27.B1, 9.1, and 9.5, as well as for the lines 26T0-1 
and 26T0-5, peptides were not detected in the initial screening, 
which used B6 and BALB/c extracts. Since all five CTL recog- 
nize,  to a greater or lesser extent, cold RMA-S cells (Table 
1), we considered them as candidates for CTL capable of recog- 
nizing empty MHC molecules. However, we found later that 
27.B1 recognizes fraction 32 of RMA extracts (Table 3). Al- 
though this fraction yidded 90% lysis, it was only 10-fold 
over detection limit, as observed in a titration experiment 
(not shown). It is therefore possible that due to cell type- 
specific differences in quantities ofpeptide content, we could 
not detect this peptide in B6 spleen cells. Consequently, our 
inability to detect peptides recognized by the remaining four 
CTL does not establish  that these recognize empty MHC 
molecules. The fact that the latter four CTL lines react against 
cold RMA-S cells is also inconclusive,  since we have found 
that several  of our peptide-dependent clones (27.5, 27.7, 27.B2, 
and 9.6) react with cold RMA-S cells (Table 1). The peptide- 
specific CTL line 26T0-3, which also recognizes cold RMA- 
S cells (Table 1), detects its peptide in material eluted from 
purified K b molecules prepared from cold RMA-S cells (Fig. 
3 e). The same is true for the clone 27.B2 (not shown). Fur- 
thermore, the peptide for 27.7 could be extracted from cold 
(but not warm) RMA-S cells, albeit hardly above detection 
limit (Table 3). In addition, the minor H-specific lines 17S0- 
1 (BALB.B anti RMA) and 17S0-3 (BALB.B anti RMA-S) 
also recognize cold as well as warm KMA-S cells (Table 1). 
Other minor H-specific CTL (A.BY  anti RMA-S) recog- 
nize peptides eluted from K b molecules prepared from cold 
RMA-S cells (not shown). 
We conclude that not all of the MHC molecules of RMA-S 
coming out in the cold are empty (29), and that recognition 
of cold RMA-S cells by T cells does not indicate that these 
T cells recognize empty MHC molecules. In another recent 
report suggesting recognition of empty MHC molecules by 
T  cells, the absence of peptides could not be formally ex- 
cluded (25).  Thus, the major question posed in this para- 
graph is still open. 
Classification.  The following attempt at classification of 
alloreactive  T  cells is partially hypothetical; we feel, how- 
ever, that it will simplify future discussions. 
The four lines without detectable peptide involvement are 
still candidates for the ability to recognize "empty" MHC 
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of alloreactive T cells np (for no peptide detectably involved). 
Alloreactive T cells that are demonstrated to recognize empty 
MHC molecules may then be allocated to an as yet hypothetical 
mt category. The 11 peptide-dependent lines fall into at least 
four categories: those recognizing a peptide produced by the 
target cell in a strictly MHC allele-specific way (for example, 
9.6, 27.7) are termed fp (for peptide faithfully MHC depen- 
dent); those recognizing peptides occurring in the context 
of more than one MHC molecule (for example, 27.B2) are 
termed pp (for dependent on promiscuous peptides); those 
for which various peptides suffice (for example, probably DV0- 
4)  are termed vp. Although the existence of this category 
is not proven by our present data, we include this category 
here for theoretical reasons. In addition, we now have pre- 
liminary data on a CTL clone that probably will prove the 
existence of this category (M. Opladen et al., unpublished 
data), Finally, those CTL that recognize a distinct, but MHC- 
independent peptide (for example, 27.5) are termed ip. The 
peptides recognized by alloreactive T  cells should then be 
classified accordingly into fp, pp, vp, or ip peptides. The only 
T cell category whose members can belong to a second cate- 
gory as well is ip, as exemplified by 27.5, which recognizes 
a KbmZ-dependent peptide in addition to an ip peptide. More 
categories might be found when alloreactive T cells from other 
strain combinations are being tested. 
Discussion 
We have analyzed the relatively low number of 16 K b- 
directed alloreactive CTL lines for their peptide involvement. 
Most of these CTL lines show peptide dependency; all CTL 
but one pair are different from each other. The number of 
different aUoreactive CTL nominally reacting against a single 
MHC molecule, therefore, must be large, confirming the con- 
clusion reached by analyzing alloreactive CTL by crossreac- 
tivity patterns  (41,  42).  It should be noted, however, that 
we have taken into consideration only CTL reactive against 
a single MHC molecule, and most of these CTL were de- 
rived in a single strain combination, bin1 anti-B6. 
Taking into account the different peptides recognized by 
our alloreactive CTL, the enormous number of combinato- 
rial possibilities for binding of cellular peptides to MHC mol- 
ecules appears to be the reason for the complexity of alloreac- 
tivity (15).  In addition, alloreactive T  cells  may recognize 
conformational differences between MHC molecules largely 
independent of the peptides bound (category vp), or even 
on empty MHC molecules, although no condusive evidence 
has been found to formally demonstrate T  cell recognition 
of empty MHC molecules. Thus, the density hypothesis (23, 
24) and the peptide hypothesis (15) are not mutually exclu- 
sive;  both phenomena might contribute to alloreactivity. 
As in the case of minor H  and viral peptides (10,  11), the 
MHC molecules themselves appear to be involved in the pro- 
duction, or at least in the maintenance, of a portion (the fp 
and pp categories) of the peptides involved in T cell allorecog- 
nition, and probably of all those peptides naturally presented 
by MHC dass I molecules. Otherwise, it would be hard to 
understand why some peptides occur only in cells expressing 
particular MHC molecules. Note that most experiments in 
this paper involve peptide extracts from entire cells, and not 
from purified MHC molecules. Several models possibly ex- 
plaining the MHC dependency of peptides occurring in cells 
(including determinant protection or the hypothesis of MHC 
being itself a protease)  are put together in reference 10. 
For the H-4 b minor histocompatibility antigen, we de- 
tected two peptides. One is MHC dependent, the other is 
MHC independent (10). We speculated that the latter might 
be a larger precursor molecule from which the smaller, MHC- 
dependent, peptide is derived upon interaction with MHC. 
The same precursor-endproduct relation could apply for the 
MHC  independent ip peptide at fraction 30/31  of all cell 
extracts, and the MHC-dependent pp peptide at fraction 25 
of bm3 extracts, both recognized by 27.5 CTL. 
It will be interesting to determine the relative frequencies 
of the categories of alloreactive CTL proposed above, and 
of other categories likely to be discovered. This should be 
carried out in several MHC-incompatible responder-stimulator 
combinations, the outcome of which might depend on the 
amount and quality of differences between MHC molecules 
of responder and stimulator cells. For example, the H-ZK bin1 
molecule differs from K b at three amino acid residues (31), 
all located at the supposed peptide binding sites (13, 14). Thus, 
it is possible that the combination bml against K b or vice 
versa is prone to give rise to especially high frequencies of 
peptide-dependent alloreactive T  cells.  On the other hand, 
reactions across unrelated MHC alleles differing in as much 
as 40 amino acid residues (many of which are at  sites not 
directly involved with peptide binding) might yield more T 
cells of the mt category (if it exists) or more of the vp type, 
or of as yet unknown categories. However, the strength of 
T cell reactions in vivo (graft rejection) and in vitro (precursor 
frequencies) across single-amino acid vs. 40-amino add MHC 
differences are within the same range (2-4). This argues against 
a principal difference in alloreactivity across related vs. un- 
related MHC incompatibilities and suggests that what we 
see in the combination bml anti-B6 is reflecting the general 
phenomenon. 
For class 1-restricted CTL, we have shown that the corre- 
sponding proteins giving rise to the peptides can be located 
in several cellular compartments (35). It is likely that the same 
applies to aUoreactive CTL. Some T cells have been reported 
to recognize peptides derived from MHC molecules (19-21). 
The frequency of alloreactive CTL with specificity for MHC- 
derived peptides remains to be determined; in principle, there 
is no reason to assume that such T  cells should occur with 
higher frequency than those specific for any other peptide. 
One important problem pertinent to T cell alloreactivity, 
namely the reason for the strong primary in vitro response, 
is not solved by our results. One hypothesis invokes the high 
density of MHC determinants presented by a cell, as opposed 
to the relatively low density of determinants composed of 
MHC and any given particular peptide (23, 24). This expla- 
nation holds only for alloreactive mt or vp T cells. Since we 
find aUoreactive T  cells that recognize specific peptides no 
more abundant than minor histocompatibility peptides (Fig. 
1068  Natural Peptides Recognized by AUoreactive T Cells 3, c and d), determinant density cannot explain alloreactivity 
entirely. Here it is important to note that while most of the 
CTL (the 13V0-5 series) tested here were derived from mice 
immunized once in vivo, the line 26T0-3, which is also pep- 
tide specific, was derived from a primary MLC. Thus, our 
data do not offer an explanation for the in vitro activation 
of unprimed alloreactive CTL, although the data explain the 
high frequency and complexity of alloreactive CTL by the 
large number of combinatorial self peptide/MHC possibilities. 
Our data on RMA-S cells seem to contradict previously 
reported results.  It has been reported that RMA-S cells are 
not recognized by bulk cultures of minor H-specific CTL, 
that they are not rejected by minor H-incompatible recip- 
ient mice, and that virus-infected RMA-S cells are not seen 
by virus-specific  CTL (27-30).  In addition, incubation of 
RMA-S cells with MHC-binding peptides increases the den- 
sity of detectable cell surface class I molecules. If cultured 
at 26~  RMA-S cells also increase expression of detectable 
MHC class I molecules, which then can be stabilized by adding 
MHC binding peptides (27, 29). It was concluded that RMA-S 
cells have a defect in peptide handling, and that they express 
empty MHC molecules, which are unstable at the cell sur- 
face at 37~  The recognition of RMA-S cells by alloreactive 
CTL was taken as evidence for recognition of empty MHC 
molecules. Since we find recognition of RMA-S cells by 
peptide-specific alloreactive CTL and also by minor H-specific 
CTL, and since we can elute peptides from R/VIA-S-derived 
K b molecules, we conclude that  the previously observed 
failure  of RMA-S cells to produce peptides in the MHC- 
restricted presentation pathway is not absolute.  We should 
note here that RMA-S cells behave in our hands as described 
earlier,  as far as immunofinorescence intensity tested with 
MHC-specific antibodies is concerned (not shown). In addi- 
tion, minor H-specific CTL derived directly from bulk cul- 
tures (29) do not kill RMA-S cells also in our hands (not 
shown). One possibility for the apparent discrepancy is that 
RMA-S cells may have a defect limiting the amount of a given 
peptide to be presented, so that only the most abundant pep- 
tides are presented efficiently enough to be recognized by T 
cells. Another possibility is that RMA-S cells can present only 
a selected set of peptides, for example those derived from pro- 
teins present in the endoplasmic reticulum (ER). 1 It has 
been speculated  that the defect in RMA-S cells lies in the 
failure of transporting peptides from the cytosol to the ER 
(27, 43). Regardless of the reason behind the defect of RMA-S 
cells, it is clear that these mutant cells are extremely useful. 
The presentation of a few peptides by these cells does not 
take away from their value for studying MHC biology. 
One view of the interaction between TCR and MHC/pep- 
tide is that the TCR is in physical contact with both latter 
molecules (44). Another view is that the TCR touches only 
the peptide and that the apparent MHC specificity of T ceils 
is imposed by the nature of the peptide selected by MHC 
molecules for binding (45).  A  third possibility is that the 
TCR touches only the MHC molecule, on which bound pep- 
1 Abbreviation  used in this paper:  ER, endoplasmic reticulum. 
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tides can impose confirmational changes.  Our data appear 
to argue against the second view, since we find that one pep- 
tide, which is presented by three different MHC molecules 
(K  bml, K bm3, and Kb),  is recognized by the TCR of clone 
27.B2 only in the context of one of these (Kb). One could 
still argue that MHC imposes a change in conformation upon 
bound peptides, which is then seen by the TCR. However, 
since MHC class I molecules generally present nonapeptides 
or octapeptides (this notion is based on the finding that most 
naturally processed viral and self peptides are nonapeptides 
or octapeptides; 11, 12, 46); the change in conformation  would 
therefore have to be imposed on such small peptides. 
A pertinent question is whether there is any physiological 
function for the obviously enormous number of different self 
peptides presented by normal cells. It is likely that that high 
number is a consequence of the cell's inability to discriminate 
between self and nonself: presentation of as many peptides 
as possible would represent sdective advantage by increasing 
the chance of presenting peptides derived from pathogens. 
In addition, however, it is possible that the many different 
presented self peptides are the ones involved in positive selec- 
tion of immature T ceils in the thymus (47),  since indirect 
evidence indicated involvement of peptides in positive selec- 
tion (48, 49). If the set of self peptides presented by thymic 
epithdium, which induces positive sdection (50), is roughly 
the same as found in spleen cells, for example, one would 
have to assume that immature T ceils are selected to recog- 
nize this multitude of sdf peptides with low affinity, which 
is enough for inducing the differentiation sigual required by 
the T ceils at that stage, but not enough to trigger mature 
T cells. Thereby, T cells would be selected to preferentially 
recognize any peptide together with sdf MHC, under the 
assumption that those T cells with low affinity for self pep- 
tides presented on self MHC tend to crossreact with high 
affinity to other peptides presented by the same MHC. This 
model would imply that immature T  cells are selected ac- 
cording to their ability to react with the allele-specific pep- 
tide motifs presented by self MHC class I molecules (46). 
The conserved epitope recognized by the clone 27.5 ap- 
pears to be a curiosity, since it is found in all the eukaryotes 
looked at (mouse, man, and annelide, and yeast) but not in 
a prokaryote. It will certainly be of academic interest to iden- 
tiff] this peptide; candidates  for it include peptides derived 
from conserved proteins such as histones or ubiquitin, which 
have then to be cut by MHC-independent proteases. Alter- 
natively, the peptide might occur in ceils as such. It is con- 
ceivable, for example, that a leader peptide, which is essen- 
tially a leftover product after a leader-containing protein has 
entered the ER and had its leader clipped off, binds to MHC 
molecules in the ER, and is then trimmed to the form finally 
presented. What the conserved peptide seen by 27.5 certainly 
illustrates, however, is the complexity of T cell alloreactivity. 
It appears that any self peptide, fulfilling the allele-specific 
requirements for MHC class I-restricted presentation (46), 
can be presented by MHC and serve as target for alloreactive 
T  cells. 
In conclusion, we have shown that alloreactive T cells nomi- 
nally directed against a single MHC class I molecule show a high degree of complexity in their peptide specificities. It 
will be of interest to identify the peptides involved using new 
technologies (11, 46). Molecular information on the peptides 
involved in allorecognition and the corresponding proteins 
should further our understanding of MHC-restricted antigen 
presentation, self tolerance, and, as mentioned before, of posi- 
tive thymic selection. 
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